Browsing by Author Lomax, Anna

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2016Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien LifehouseBeith, Jane; Bhadri, Vivek; Boyer, Michael; Grimison, Peter; Horvath, Lisa; Kao, Steven; McNeil, Catriona; Tattersall, Martin; Lomax, Anna; Thomas, David; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineOutcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse, Internal Medicine Journal, vol.46, 12, 2016,pp 1392-1398
2013Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN trialSambrook, Philip; Abdi, Ehtesham; Beith, Jane M.; Bell, Richard (Prof); Broad, A; Henry, Margaret; Lee, Chooi; Lomax, Anna; Pocock, Nicholas; Sewak, Sanjeev; White, Karen; Yap, Saw Yee; Yeow, Elaine; Northern Clinical School: MedicinePrevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN trial, Journal of Bone Oncology, vol.2, 4, 2013,pp 145-153
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210